Remember this?
https://www.scripps.edu/news-and-events/press-room/2020/20200416-drug-repurposing-reframe-covid19.html
And this is what they came up with in 2021--unfortunately remdesivir was one of the repurposed drugs, and the other two things mentioned, I'm not sure what became of them, but if they were used with remdesivir, it is not …
And this is what they came up with in 2021--unfortunately remdesivir was one of the repurposed drugs, and the other two things mentioned, I'm not sure what became of them, but if they were used with remdesivir, it is not encouraging. Apparently the Bill & Melinda Gates Foundation was helping.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), is sponsoring a major new antiviral drug development center that will be led by Scripps Research.
The center received an award in the amount of $67 million over 3 years, with potential renewal for two additional years, and will be known as the Center for Antiviral Medicines and Pandemic Preparedness (CAMPP). It will be one of nine NIAID-sponsored Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.
It seems like they completely ignored hydroxychloroquine, ivermectin, and the other therapeutics, fluvoxamine, and others, developed no protocol that I know of, yet have now gotten $67 million dollars. This new drug, which they say is a variation on an existing drug that can block the virus looks interesting if it works and they claim is nontoxic two nonthreatened cells--I'll bet they can patent this variation. But if it needs the normal regulatory process it could take years to come to market. Unless it gets emergency use authorization, in which case they throw out all that.
Remember this?
https://www.scripps.edu/news-and-events/press-room/2020/20200416-drug-repurposing-reframe-covid19.html
And this is what they came up with in 2021--unfortunately remdesivir was one of the repurposed drugs, and the other two things mentioned, I'm not sure what became of them, but if they were used with remdesivir, it is not encouraging. Apparently the Bill & Melinda Gates Foundation was helping.
https://www.scripps.edu/news-and-events/press-room/2021/20210602-reframe-covid19-therapies.html
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), is sponsoring a major new antiviral drug development center that will be led by Scripps Research.
And from May 18 this year:
https://www.scripps.edu/news-and-events/press-room/2022/20220518-nih-pandemic-preparedness-center.html
The center received an award in the amount of $67 million over 3 years, with potential renewal for two additional years, and will be known as the Center for Antiviral Medicines and Pandemic Preparedness (CAMPP). It will be one of nine NIAID-sponsored Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.
Now they've come up with a novel drug.
https://www.scripps.edu/news-and-events/press-room/2022/20220929-lipton-covid.html
New drug has potential to turn COVID-19 virus against itself
Scripps Research team showed that a variation of an already FDA-approved therapeutic for neurological disease can block COVID-19 infection in animals.
September 29, 2022
It seems like they completely ignored hydroxychloroquine, ivermectin, and the other therapeutics, fluvoxamine, and others, developed no protocol that I know of, yet have now gotten $67 million dollars. This new drug, which they say is a variation on an existing drug that can block the virus looks interesting if it works and they claim is nontoxic two nonthreatened cells--I'll bet they can patent this variation. But if it needs the normal regulatory process it could take years to come to market. Unless it gets emergency use authorization, in which case they throw out all that.